UK Is First To Sign Up Pfizer For COVID-19 Vaccine, AstraZeneca For Antibodies
Valneva Also Agrees 60 Million Dose Deal
Executive Summary
The UK's vaccine strategy spread its bets over three candidates so far, as the country also looks to prove its world-class status in life sciences research and manufacturing.
You may also be interested in...
UK Bags More COVID-19 Vaccines And Backs J&J, Novavax Trials
With the Janssen and Novavax deals, the UK has now secured access to six different candidates across four different vaccine types.
GSK Vaccine Sales Hit By COVID-19 But Initial Signs Of Recovery
GlaxoSmithKline sees initial signs of recovery from the coronavirus pandemic in terms of vaccination rates and highlights its growing research progress against COVID, RSV and meningitis, although a UK expert warns against over-optimism.
Initial Results Positive For Valneva/Pfizer's Lyme Disease Vaccine In First Phase II Study
Speciality vaccine biotech Valneva outlines seroconversion rates and safety of candidate Lyme disease vaccine that it is co-developing with partner Pfizer.